Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
AI-Driven Wellness Play on the CSE (click to learn more) Golden Cariboo (CSE:GCC) (OTC:GCCFF) Unlocks Cariboo Gold Potential (click to learn more) An Emerging Name in Cannabis: HERB (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Esperion Therapeutics Inc ESPR

Healthcare Drug Manufacturers - Specialty & Generic
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ESPR)

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire 1 day ago

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 11, 2026

Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2026

Esperion's Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes

GlobeNewswire December 19, 2025

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire December 9, 2025

Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

GlobeNewswire November 21, 2025

Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference

GlobeNewswire November 19, 2025

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

GlobeNewswire November 18, 2025

HLS Therapeutics Announces Health Canada Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Canada NewsWire November 18, 2025
View More News ››

Opinion & Analysis (NDAQ:ESPR)

Topline Results from Lipid-Lowering Trial 'Just What the Doctor Ordered'

Streetwise Reports September 5, 2019

Biopharma Buys 'Insurance Policy Ahead of First Commercial Launch'

Streetwise Reports July 3, 2019
View More Opinion ››

Bullboard Posts (NDAQ:ESPR)

This stock is a good buy

Buy Order was filled at $2.83 cents per share today and this one should do well for all of us shareholders.
coolfooldumbguy - December 2, 2024

Esperion Therapeutics, Inc.: Delivering Impressive Growth an

http://beyondspx.com/2024/07/31/esperion-therapeutics-inc-delivering-impressive-growth-and-expanded-indications/
MikeTester - August 2, 2024

ESPERION: REVOLUTIONIZING THE PHARMA INDUSTRY

$ESPR   Excited to share an article about Esperion Therapeutics Inc. (NASDAQ: ESPR), a pharmaceutical company...
AviseAnalytics - July 15, 2024

When will judge make decision

Agreement should be clear re milestones 
edrose - March 23, 2023

It lowers ldl but bigger question does it decrease

Heart attacks, and mortality  
edrose - March 9, 2023

ESPR Corporate and Financial Update

Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results For the full news...
BearDownAZ - May 9, 2019
View more Bullboard ››

Grizzly Discoveries Inc

Grizzly Discoveries Inc

Grizzly Discoveries Inc. engages in the acquisition, exploration, and development of precious and base metals properties ...
View More »

Podcasts